Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
about
Understanding the interplay between host immunity and Epstein-Barr virus in NPC patientsCurrent treatment options for local residual nasopharyngeal carcinomaUnusual axillary metastasis of recurrent nasopharyngeal cancer: A case report.Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population.The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational studyThe clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 casesCurrent and emerging treatment options for nasopharyngeal carcinoma.Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.Nasopharyngeal carcinoma with skull base erosion cytologic findings.Prognostic implications of post-therapy (18)F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma.False-positive finding of retropharyngeal lymph node recurrence in both fluorine (18)FDG PET and MRI in a patient with nasopharyngeal carcinoma.
P2860
Q26823898-B30C8B42-8325-478F-B591-C73BCC777940Q26852207-10C6DD11-173F-4E85-ABED-63BAB8D6BE69Q33714382-BA4C704C-76DB-46A3-9398-B965109BB06AQ34286259-686C8F0A-4169-4696-98C1-86328400D5DFQ35678382-BC3EAA71-CCE2-4107-A4FD-65BBE45447E6Q36152889-DF295533-F6F1-48AB-914B-BC910DB977F0Q36359374-50700E55-A2FE-40BC-BF60-FA83C6B126AEQ38270678-AE9ED13A-956E-423B-8099-C754D59AAD18Q41936592-071D702F-6175-4FF1-B25A-E3D7761199BDQ43527360-7E615B6A-715D-46F8-AEC7-BD7031C9A143Q45325137-8DB30D09-AE79-4685-BD71-75130CEF696EQ45351163-93069CDF-05A5-453E-A1C5-CC5C388648F9Q52991338-EF548EE5-3398-4CD2-9AF3-A51D5C215284
P2860
Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Plasma Epstein-Barr virus DNA ...... s of nasopharyngeal carcinoma.
@en
Plasma Epstein-Barr virus DNA ...... s of nasopharyngeal carcinoma.
@nl
type
label
Plasma Epstein-Barr virus DNA ...... s of nasopharyngeal carcinoma.
@en
Plasma Epstein-Barr virus DNA ...... s of nasopharyngeal carcinoma.
@nl
prefLabel
Plasma Epstein-Barr virus DNA ...... s of nasopharyngeal carcinoma.
@en
Plasma Epstein-Barr virus DNA ...... s of nasopharyngeal carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Plasma Epstein-Barr virus DNA ...... s of nasopharyngeal carcinoma.
@en
P2093
Chih-Wen Twu
Ching-Te Wu
Jin-Ching Lin
Kai-Li Liang
Kuan-Wen Chen
Wan-Yu Lin
Wen-Yi Wang
Yi-Ting Shih
P2860
P304
P356
10.1002/CNCR.26069
P407
P577
2011-03-22T00:00:00Z